Literature DB >> 24233257

Imaging changes following stereotactic radiosurgery for metastatic intracranial tumors: differentiating pseudoprogression from tumor progression and its effect on clinical practice.

Jacob Ruzevick1, Lawrence Kleinberg, Daniele Rigamonti.   

Abstract

Stereotactic radiosurgery has become standard adjuvant treatment for patients with metastatic intracranial lesions. There has been a growing appreciation for benign imaging changes following radiation that are difficult to distinguish from true tumor progression. These imaging changes, termed pseudoprogression, carry significant implications for patient management. In this review, we discuss the current understanding of pseudoprogression in metastatic brain lesions, research to differentiate pseudoprogression from true progression, and clinical implications of pseudoprogression on treatment decisions.

Entities:  

Mesh:

Year:  2013        PMID: 24233257      PMCID: PMC4086651          DOI: 10.1007/s10143-013-0504-8

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  90 in total

1.  Can standard magnetic resonance imaging reliably distinguish recurrent tumor from radiation necrosis after radiosurgery for brain metastases? A radiographic-pathological study.

Authors:  Ivan M Dequesada; Ronald G Quisling; Anthony Yachnis; William A Friedman
Journal:  Neurosurgery       Date:  2008-11       Impact factor: 4.654

2.  Early brain tumor metastasis reduction following Gamma Knife surgery.

Authors:  Arnaldo Neves Da Silva; Kazuki Nagayama; David Schlesinger; Jason P Sheehan
Journal:  J Neurosurg       Date:  2009-03       Impact factor: 5.115

3.  Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas.

Authors:  Shin-Ichi Miyatake; Shinji Kawabata; Naosuke Nonoguchi; Kunio Yokoyama; Toshihiko Kuroiwa; Hideki Matsui; Koji Ono
Journal:  Neuro Oncol       Date:  2009-03-16       Impact factor: 12.300

Review 4.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.

Authors:  Randy L Jensen
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

Review 5.  Stereotactic radiosurgery for the treatment of brain metastases.

Authors:  Falk Müller-Riemenschneider; Angelina Bockelbrink; Iris Ernst; Christoph Schwarzbach; Christoph Vauth; J-Matthias Graf von der Schulenburg; Stefan N Willich
Journal:  Radiother Oncol       Date:  2009-01-08       Impact factor: 6.280

6.  NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.

Authors:  Alexander M Spence; Mark Muzi; Jeanne M Link; Finbarr O'Sullivan; Janet F Eary; John M Hoffman; Lalitha K Shankar; Kenneth A Krohn
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

7.  Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions.

Authors:  Ethan A Smith; Ruth C Carlos; Larry R Junck; Christina I Tsien; Augusto Elias; Pia C Sundgren
Journal:  AJR Am J Roentgenol       Date:  2009-02       Impact factor: 3.959

8.  Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.

Authors:  R F Barajas; J S Chang; P K Sneed; M R Segal; M W McDermott; S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2008-11-20       Impact factor: 3.825

9.  Metabolic alterations: a biomarker for radiation-induced normal brain injury-an MR spectroscopy study.

Authors:  P C Sundgren; V Nagesh; A Elias; C Tsien; L Junck; D M Gomez Hassan; T S Lawrence; T L Chenevert; L Rogers; P McKeever; Y Cao
Journal:  J Magn Reson Imaging       Date:  2009-02       Impact factor: 4.813

10.  Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence.

Authors:  Friso W A Hoefnagels; Frank J Lagerwaard; Esther Sanchez; Cornelis J A Haasbeek; Dirk L Knol; Ben J Slotman; W Peter Vandertop
Journal:  J Neurol       Date:  2009-03-10       Impact factor: 4.849

View more
  15 in total

1.  Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.

Authors:  Paul D Brown; Karla V Ballman; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Anthony C Whitton; Jeffrey Greenspoon; Ian F Parney; Nadia N I Laack; Jonathan B Ashman; Jean-Paul Bahary; Costas G Hadjipanayis; James J Urbanic; Fred G Barker; Elana Farace; Deepak Khuntia; Caterina Giannini; Jan C Buckner; Evanthia Galanis; David Roberge
Journal:  Lancet Oncol       Date:  2017-07-04       Impact factor: 41.316

2.  Distinguishing True Progression From Radionecrosis After Stereotactic Radiation Therapy for Brain Metastases With Machine Learning and Radiomics.

Authors:  Luke Peng; Vishwa Parekh; Peng Huang; Doris D Lin; Khadija Sheikh; Brock Baker; Talia Kirschbaum; Francesca Silvestri; Jessica Son; Adam Robinson; Ellen Huang; Heather Ames; Jimm Grimm; Linda Chen; Colette Shen; Michael Soike; Emory McTyre; Kristin Redmond; Michael Lim; Junghoon Lee; Michael A Jacobs; Lawrence Kleinberg
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-05-24       Impact factor: 7.038

3.  Pseudo-progression after stereotactic radiotherapy of brain metastases: lesion analysis using MRI cine-loops.

Authors:  Ruud Wiggenraad; Petra Bos; Antoinette Verbeek-de Kanter; Geert Lycklama À Nijeholt; Jan van Santvoort; Martin Taphoorn; Henk Struikmans
Journal:  J Neurooncol       Date:  2014-07-05       Impact factor: 4.130

4.  Value of serial magnetic resonance imaging in the assessment of brain metastases volume control during stereotactic radiosurgery.

Authors:  Gianvincenzo Sparacia; Francesco Agnello; Aurelia Banco; Francesco Bencivinni; Andrea Anastasi; Giovanna Giordano; Adele Taibbi; Massimo Galia; Tommaso Vincenzo Bartolotta
Journal:  World J Radiol       Date:  2016-12-28

5.  Treatment of MRI-Diagnosed Trigeminal Peripheral Nerve Sheath Tumors by Stereotactic Radiotherapy in Dogs.

Authors:  K S Hansen; A L Zwingenberger; A P Théon; I Pfeiffer; M S Kent
Journal:  J Vet Intern Med       Date:  2016-06-08       Impact factor: 3.333

6.  Effect of Gamma Knife Radiosurgery and Programmed Cell Death 1 Receptor Antagonists on Metastatic Melanoma.

Authors:  Nathan Nordmann; Molly Hubbard; Tyler Nordmann; Paul W Sperduto; H Brent Clark; Matthew A Hunt
Journal:  Cureus       Date:  2017-12-13

7.  A simple score to estimate the likelihood of pseudoprogression vs. recurrence following stereotactic radiosurgery for brain metastases: The Bergen Criteria.

Authors:  Bente Sandvei Skeie; Per Øyvind Enger; Jonathan Knisely; Paal-Henning Pedersen; Jan Ingeman Heggdal; Geir Egil Eide; Geir Olve Skeie
Journal:  Neurooncol Adv       Date:  2020-03-10

8.  Differentiating Radiation-Induced Necrosis from Recurrent Brain Tumor Using MR Perfusion and Spectroscopy: A Meta-Analysis.

Authors:  Ming-Tsung Chuang; Yi-Sheng Liu; Yi-Shan Tsai; Ying-Chen Chen; Chien-Kuo Wang
Journal:  PLoS One       Date:  2016-01-07       Impact factor: 3.240

9.  Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment.

Authors:  Maike Trommer-Nestler; Simone Marnitz; Martin Kocher; Daniel Rueß; Max Schlaak; Sebastian Theurich; Michael von Bergwelt-Baildon; Janis Morgenthaler; Karolina Jablonska; Eren Celik; Maximilian I Ruge; Christian Baues
Journal:  Int J Mol Sci       Date:  2018-09-07       Impact factor: 5.923

10.  Analysis of MRI Volumetric Changes After Hypofractionated Stereotactic Radiation Therapy for Benign Intracranial Neoplasms.

Authors:  Kathryn R Fega; Geoffrey P Fletcher; Mark R Waddle; Jennifer L Peterson; Jonathan B Ashman; David M Barrs; Bernard R Bendok; Naresh P Patel; Alyx B Porter; Sujay A Vora
Journal:  Adv Radiat Oncol       Date:  2018-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.